After 48 years at the heart of the business he built from a single Johannesburg pharmacy, Ivan Saltzman is stepping back. The 76-year-old founder of Dis-Chem retires from his executive role at the end of June, remaining on the board as non-executive deputy chairman — a quiet but significant moment for one of South Africa’s biggest listed retailers.
Saltzman and his wife, Lynette, both pharmacists, opened the first Dis-Chem store in 1978, disrupting a market in which medicine prices were largely unregulated by undercutting rivals on prescription drugs. The chain grew into a roughly US$1.7 billion healthcare retailer spanning three countries, with stores that doubled as one-stop wellness destinations selling vitamins, cosmetics and their own private-label goods.
A test of culture
His departure hands a generational challenge to chief executive Rui Morais, a company insider who worked on the Dis-Chem listing and took the top job about three years ago. The worry, voiced by several analysts, is whether the entrepreneurial instinct that powered Dis-Chem’s rise can survive the shift to professional management. South African retail offers cautionary tales: the Ackerman family’s drawn-out succession at Pick n Pay, and the upheaval around Steinhoff and Pepkor, both show how founder-led empires can stumble when control changes hands.
The Saltzman family is not walking away entirely. Ivan and Lynette gifted shares to two of their sons before his retirement, keeping the family’s stake above a quarter of the company. Bloomberg, valuing the family for the first time, puts its fortune at around US$1.3 billion.
Betting on healthcare
Morais is steering Dis-Chem deeper into healthcare, building Health Hub stores that combine a pharmacy, clinic, diagnostic testing, virtual doctor consultations and medical-insurance services under one roof. The aim is to cut dispensing times and reposition the group as an integrated healthcare platform rather than a traditional retailer. It is a bold strategy, and a risky one: Dis-Chem shares fell sharply in late May after earnings missed expectations, weighed down by upfront spending on a new innovation hub.
As Merchant West’s Alyssa Viljoen cautioned, insurance and healthcare are regulated and capital-intensive — a world apart from pharmacy retail — and the market will not give management unlimited time to prove the new model. Saltzman’s exit, then, marks not just the end of an era but the start of Dis-Chem’s most consequential bet yet.
